Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibru...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Fraietta, Joseph A., Beckwith, Kyle A., Patel, Prachi R., Ruella, Marco, Zheng, Zhaohui, Barrett, David M., Lacey, Simon F., Melenhorst, Jan Joseph, McGettigan, Shannon E., Cook, Danielle R., Zhang, Changfeng, Xu, Jun, Do, Priscilla, Hulitt, Jessica, Kudchodkar, Sagar B., Cogdill, Alexandria P., Gill, Saar, Porter, David L., Woyach, Jennifer A., Long, Meixiao, Johnson, Amy J., Maddocks, Kami, Muthusamy, Natarajan, Levine, Bruce L., June, Carl H., Byrd, John C., Maus, Marcela V.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2016
主題:
Immunobiology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778162/
https://ncbi.nlm.nih.gov/pubmed/26813675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-679134
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料